Wright TC, et al. - In this study including 2807 subjects (≥21 years) with atypical squamous cells-undetermined significance (ASC-US) or low-grade squamous intraepithelial lesions (LSIL) cytology from the baseline phase of the Onclarity HPV trial, researchers focused on use of human papillomavirus (HPV) genotyping as a risk-based triage approach for women with ASC-US and LSIL cytology. In both of these populations, HPV 16 was found to carry the highest risk for cervical intraepithelial neoplasia grade 2 or worse (≥CIN2). For women with ASC-US and LSIL, although somewhat varied risk of ≥CIN3 and ≥CIN2 related to the other 13 genotypes was found but an intermediate risk band included HPV 31, 18, 33/58, 51 and 52. In the ≥21 year-old ASC-US and LSIL populations, multiple risk bands for ≥CIN3 and ≥CIN2 were discovered with HPV genotyping in this study. Based on these findings, a 1-year follow-up period to preclude immediate colposcopy is supported for ASC-US or LSIL women positive for the lowest-risk HPV genotypes.